State Street Corporation, a financial services and bank holding company headquartered in Boston, Massachusetts, has filed an amended Schedule 13G with the United States Securities and Exchange Commission (SEC) on June 30, 2024, indicating a significant ownership stake in Altimmune Inc., a biopharmaceutical company. According to the filing, State Street Corporation has shared voting power over 3,667,576 shares and shared dispositive power over 3,909,286 shares of Altimmune's common stock. The filing asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Altimmune Inc. The subsidiaries of State Street Corporation listed in the filing as beneficial owners of the securities include SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, and State Street Global Advisors Trust Company, all classified as investment advisors (IA).

State Street Corporation, a financial services and bank holding company headquartered in Boston, Massachusetts, has filed an amended Schedule 13G with the United States Securities and Exchange Commission (SEC) on June 30, 2024, indicating a significant ownership stake in Altimmune Inc., a biopharmaceutical company. According to the filing, State Street Corporation has shared voting power over 3,667,576 shares and shared dispositive power over 3,909,286 shares of Altimmune's common stock. The filing asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Altimmune Inc. The subsidiaries of State Street Corporation listed in the filing as beneficial owners of the securities include SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, and State Street Global Advisors Trust Company, all classified as investment advisors (IA).